Navigation Links
Covance Elects Bradley T. Sheares to Company's Board of Directors
Date:2/19/2009

PRINCETON, N.J., Feb. 19 /PRNewswire-FirstCall/ -- Covance Inc. (NYSE: CVD) today announced that it has elected Bradley T. Sheares, Ph. D., to its Board of Directors.

Dr. Sheares is former chief executive officer and member of the Board of Directors of Reliant Pharmaceuticals, Inc., a pharmaceutical company that marketed a portfolio of branded cardiovascular medicines. Prior to joining Reliant, he was president of the U.S. Human Health division of Merck and Co., Inc., where he led commercial efforts in the United States for the company's portfolio of prescription medicines for the treatment of chronic and acute diseases. In addition to this role, Dr. Sheares was a member of Merck's management committee, which was responsible for formulating global business strategies, managing operations and setting corporate policies. He joined Merck in 1987 as research fellow in the Merck Research Laboratories, and he held positions of increasing responsibility in Merck until his departure in 2006.

"We are very pleased to welcome Dr. Sheares to our Board of Directors. His scientific background, academic achievements and extensive experience in bringing new medicines to the market will strengthen Covance's ability to provide innovative drug development solutions to our clients, " said Joe Herring, Covance chairman and CEO. "We look forward to leveraging Dr. Sheares' outstanding record of leadership and management, as well as his focus on recruiting top talent, to help our company sustain its leadership position in the industry and continue to provide value to our shareholders and employees."

"Covance has been at the forefront of creating innovative models of outsourcing," said Dr. Sheares. "I am thrilled at the opportunity to be part of such an accomplished group of individuals and to leverage my health care experience in enhancing the company's ability to deliver high-quality service and integrated solutions to its clients."

Dr. Sheares also serves on the Board of Directors of Honeywell International, a diversified technology and manufacturing company, and The Progressive Corporation, one of the nation's largest insurance holding companies. In addition, he serves on the Board of Trustees of Spelman College and is a member of the College of Physicians of Philadelphia, the Abington Friends School Committee, the Scientific Advisory Council for Montclair State University, and the Executive Leadership Council. He is the former chair of the Board of Directors of the National Pharmaceutical Council, which focuses on broadly communicating the economic, clinical and societal value of pharmaceuticals.

Dr. Sheares graduated summa cum laude with a bachelor's degree in chemistry from Fisk University and earned his doctorate in biochemistry from Purdue University. He completed his postdoctoral training as a Lucille P. Markey Scholar and NIH Research Fellow at the Massachusetts Institute of Technology.

Covance, with headquarters in Princeton, New Jersey, is one of the world's largest and most comprehensive drug development services companies with annual revenues greater than $1.7 billion, global operations in more than 20 countries, and more than 9,600 employees worldwide. Information on Covance's products and services, recent press releases, and SEC filings can be obtained through its website at www.covance.com.


'/>"/>
SOURCE Covance Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Covance to Present at the 2009 UBS Global Healthcare Services Conference
2. Covance Opens Three New Offices in Ukraine, Slovakia, and Israel
3. Covance Reports Fourth Quarter and Full-Year 2008 Results
4. Covance to Present at the 27th Annual J.P. Morgan Healthcare Conference
5. Covance Inc. Invites You to Join the Webcast of Its Fourth Quarter 2008 Financial Results Conference Call
6. Covance Inc. Invites You to Join the Webcast of Its 2009 Guidance Conference Call
7. Covance to Present at the Credit Suisse 2008 Healthcare Conference
8. Covance and Lilly Enter Into a Strategic R&D Collaboration
9. Covance Recognized for Outstanding Performance by Merck & Co., Inc.
10. Covance Recognized for Outstanding Customer Service by Eli Lilly and Company
11. Covance Inc. Invites You to Join the Webcast of Its Second Quarter 2008 Financial Results Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... The OSHA ... Training Institute Education Center headquartered in Northern California, has issued an important reminder ... at their worksites. Employers with workers exposed to high temperatures should establish ...
(Date:6/27/2016)... ... June 27, 2016 , ... "FCPX editors can now ... of Final Cut Pro X," said Christina Austin - CEO of Pixel Film Studios. ... Final Cut Pro X users can now reveal the media of their split ...
(Date:6/27/2016)... (PRWEB) , ... June 27, 2016 , ... ... for mental health professionals, announced today its affiliation with Tennessee Counseling Association. ... solutions to the network of the Tennessee Counseling Association, adding exclusive benefits and ...
(Date:6/27/2016)... ... June 27, 2016 , ... ... payment industry today announced its strategic partnership with Connance, a healthcare industry ... The two companies’ proven, proprietary technology combine to provide health systems, hospitals ...
(Date:6/27/2016)... ... June 27, 2016 , ... A revolution ... the emergency ambulance transport experience for the millions of people who require these ... disrupted the taxi industry through the use of technology. Now, SmartEMS has put ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... 2016 One of Australia,s successful ... of a new biotechnology company, Noxopharm Limited [ABN 50 608 966 ... and to list on the ASX. Noxopharm is a ... enter a Phase 1 clinical study later this year. ... of the biggest problems facing cancer patients - the ability of ...
(Date:6/26/2016)... 2016 Jazz Pharmaceuticals plc (Nasdaq: ... Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended ("HSR"), ... Inc. ("Celator"; Nasdaq: CPXX ) expired effective ... As previously announced on May 31, 2016, ... agreement under which Jazz Pharmaceuticals has commenced a tender ...
(Date:6/26/2016)... -- VMS Rehab Systems, Inc. ( www.vmsrehabsystemsinc.com ) reported today ... to build a strong and stable market for trading ... the OTC Markets-pink current trading platform. Explains ... seeing an anomaly in market trading activities that may ... Company, but shareholders and market players as well. I ...
Breaking Medicine Technology: